Royal London Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $250M | Sell |
508,538
-32,387
| -6% | -$17.6M | 0.52% | 28 |
|
|
2025
Q4 | $313M | Sell |
540,925
-40,352
| -7% | -$22.8M | 0.66% | 19 |
|
|
2025
Q3 | $282M | Sell |
581,277
-10,680
| -2% | -$4.97M | 0.61% | 22 |
|
|
2025
Q2 | $240M | Sell |
591,957
-145,479
| -20% | -$60.8M | 0.55% | 30 |
|
|
2025
Q1 | $367M | Sell |
737,436
-21,494
| -3% | -$11.6M | 0.87% | 18 |
|
|
2024
Q4 | $395M | Sell |
758,930
-11,486
| -1% | -$6.31M | 0.96% | 17 |
|
|
2024
Q3 | $477M | Sell |
770,416
-56,392
| -7% | -$33.4M | 1.17% | 12 |
|
|
2024
Q2 | $457M | Sell |
826,808
-49,070
| -6% | -$28.1M | 1.17% | 12 |
|
|
2024
Q1 | $509M | Buy |
875,878
+7,485
| +0.9% | +$4.2M | 1.27% | 11 |
|
|
2023
Q4 | $461M | Buy |
868,393
+8,518
| +1% | +$4.12M | 1.32% | 9 |
|
|
2023
Q3 | $435M | Buy |
859,875
+22,409
| +3% | +$11.9M | 1.41% | 9 |
|
|
2023
Q2 | $437M | Buy |
837,466
+48,322
| +6% | +$26.1M | 1.41% | 9 |
|
|
2023
Q1 | $455M | Buy |
789,144
+14,740
| +2% | +$8.31M | 1.82% | 7 |
|
|
2022
Q4 | $427M | Buy |
774,404
+4,775
| +0.6% | +$2.53M | 1.91% | 7 |
|
|
2022
Q3 | $391M | Buy |
769,629
+10,252
| +1% | +$5.74M | 1.98% | 6 |
|
|
2022
Q2 | $413M | Buy |
759,377
+7,130
| +0.9% | +$3.92M | 1.91% | 6 |
|
|
2022
Q1 | $445M | Buy |
752,247
+4,762
| +0.6% | +$2.74M | 1.74% | 8 |
|
|
2021
Q4 | $499M | Sell |
747,485
-7,360
| -1% | -$4.6M | 1.86% | 8 |
|
|
2021
Q3 | $431M | Buy |
754,845
+3,552
| +0.5% | +$1.95M | 1.75% | 8 |
|
|
2021
Q2 | $379M | Buy |
751,293
+193,915
| +35% | +$91.5M | 1.55% | 9 |
|
|
2021
Q1 | $255M | Buy |
557,378
+56,259
| +11% | +$26.9M | 1.17% | 14 |
|
|
2020
Q4 | $233M | Sell |
501,119
-7,056
| -1% | -$3.31M | 1.22% | 12 |
|
|
2020
Q3 | $221M | Buy |
508,175
+95,878
| +23% | +$39.6M | 1.34% | 11 |
|
|
2020
Q2 | $145M | Buy |
412,297
+12,093
| +3% | +$4.05M | 1.01% | 15 |
|
|
2020
Q1 | $114M | Buy |
400,204
+127,098
| +47% | +$40.1M | 0.92% | 17 |
|
|
2019
Q4 | $88.8M | Buy |
273,106
+12,616
| +5% | +$3.83M | 0.61% | 32 |
|
|
2019
Q3 | $75.9M | Sell |
260,490
-2,125
| -0.8% | -$609K | 0.57% | 35 |
|
|
2019
Q2 | $77.1M | Buy |
262,615
+5,855
| +2% | +$1.61M | 0.73% | 26 |
|
|
2019
Q1 | $70.3M | Buy |
256,760
+13,737
| +6% | +$3.42M | 0.55% | 37 |
|
|
2018
Q4 | $54.1M | Buy |
243,023
+66,393
| +38% | +$15.6M | 0.47% | 45 |
|
|
2018
Q3 | $43.1M | Buy |
176,630
+3,481
| +2% | +$801K | 0.44% | 51 |
|
|
2018
Q2 | $35.9M | Buy |
+173,149
| New | +$36.8M | 0.36% | 64 |
|
|
2016
Q2 | $19.9M | Sell |
134,358
-13,619,267
| -99% | -$2.01B | 0.32% | 71 |
|
|
2016
Q1 | $97K | Buy |
13,753,625
+13,610,871
| +9,534% | +$1.82B | 0.14% | 175 |
|
|
2015
Q4 | $20.4M | Buy |
142,754
+1,263
| +0.9% | +$168K | 0.32% | 74 |
|
|
2015
Q3 | $17.3M | Buy |
+141,491
| New | +$18.4M | 0.28% | 85 |
|
|
2014
Q4 | $159K | Buy |
125,544
+28,261
| +29% | +$3.44M | 0.3% | 85 |
|
|
2014
Q3 | $11.9M | Buy |
97,283
+4,804
| +5% | +$584K | 0.3% | 84 |
|
|
2014
Q2 | $11.1M | Sell |
92,479
-394
| -0.4% | -$46.4K | 0.26% | 95 |
|
|
2014
Q1 | $11M | Buy |
92,873
+8,138
| +10% | +$968K | 0.26% | 98 |
|
|
2013
Q4 | $9.7M | Buy |
84,735
+1,001
| +1% | +$99.5K | 0.25% | 97 |
|
|
2013
Q3 | $8.13M | Buy |
83,734
+673
| +0.8% | +$60.9K | 0.22% | 113 |
|
|
2013
Q2 | $7.09M | Buy |
+83,061
| New | +$6.91M | 0.21% | 115 |
|
Other funds holding TMO
VCM
Royal London Asset Management's TMO Position: Q1 2026 in Review
Royal London Asset Management reduced its Thermo Fisher Scientific (TMO) stake by 6% in Q1 2026, selling an estimated $17.6M and leaving 508,538 shares worth $250M. The position accounts for 0.52% of the portfolio, ranked #28.
Royal London Asset Management first reported a position in TMO in Q2 2013 and has held it in 43 quarters since. The position peaked at $509M in Q1 2024. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Royal London Asset Management held 508,538 shares of Thermo Fisher Scientific worth $250M as of Q1 2026.
- Royal London Asset Management sold 32,387 Thermo Fisher Scientific shares in Q1 2026, an estimated $17.6M.
- Thermo Fisher Scientific made up 0.52% of Royal London Asset Management's portfolio in Q1 2026, its #28 holding.
- Royal London Asset Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Thermo Fisher Scientific position peaked at $509M in Q1 2024.
- 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.